1
|
Zangani C, Giordano B, Stein H, Bonora S, D'Agostino A, Ostinelli EG. Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis. Hum Psychopharmacol 2021; 36:e2801. [PMID: 34727399 PMCID: PMC8596405 DOI: 10.1002/hup.2801] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Accepted: 05/15/2021] [Indexed: 02/06/2023]
Abstract
BACKGROUND Depressive symptoms occur in several psychiatric disorders, often in the absence of a formal diagnosis of depression. We aimed to evaluate the efficacy and the tolerability of amisulpride, both alone and as augmentation therapy, in the treatment of depressive symptoms in individuals with any major psychiatric disorder. METHODS We searched PubMed, Embase, PsycINFO, GreyLit, OpenGrey and ProQuest up to March 2020 for randomised controlled trials focussing on the treatment of an acute depressive episode in any major psychiatric disorder. A random-effect meta-analysis was performed to synthesize the findings on depressive symptoms (primary outcome), response rate and tolerability. RESULTS We retrieved 11 studies including 2065 patients with a diagnosis of dysthymia (eight studies), major depression (one study) or schizophrenia (two studies). Amisulpride 50 mg/day was associated with a larger reduction of depressive symptoms compared to placebo (standardised mean difference [SMD] = -0.70, CI 95% -0.92, -0.49; I2 = 0.0%), and was found to be comparable to selective serotonin reuptake inhibitors (SSRIs; SMD = -0.08, CI 95% -0.23, 0.06, I2 = 0.0%), amineptine, imipramine and amitriptyline in the treatment of dysthymia (three studies, not pooled). In individuals with schizophrenia, amisulpride administered at higher doses (>400 mg/day) was comparable to olanzapine and risperidone (two studies, not pooled). In terms of tolerability, amisulpride was superior to placebo for dysthymia (odds ratio [OR] = 3.94, CI 95% 1.07, 14.48; I2 = 0.0) and comparable with SSRIs (OR = 0.94, CI 95% 0.55, 1.62; I2 = 0.0%). CONCLUSION Treatment with amisulpride could be a valid choice for selected individuals with dysthymia or depressive symptoms in the context of schizophrenia. More studies on the efficacy and tolerability of amisulpride are needed to draw firm conclusions on its potential benefits in other psychiatric disorders.
Collapse
Affiliation(s)
- Caroline Zangani
- Oxford Health NHS Foundation Trust, Warneford HospitalOxfordUK,Department of PsychiatryUniversity of OxfordOxfordUK,Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research CentreOxfordUK,Department of Health SciencesUniversity of MilanMilanItaly
| | | | | | - Stefano Bonora
- Department of Health SciencesUniversity of MilanMilanItaly
| | | | - Edoardo Giuseppe Ostinelli
- Oxford Health NHS Foundation Trust, Warneford HospitalOxfordUK,Department of PsychiatryUniversity of OxfordOxfordUK,Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research CentreOxfordUK
| |
Collapse
|
2
|
Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2020; 21:523-30. [PMID: 17113759 DOI: 10.1016/j.eurpsy.2006.09.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2006] [Revised: 09/07/2006] [Accepted: 09/08/2006] [Indexed: 11/17/2022] Open
Abstract
AbstractPurposeTo compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial.PatientsEighty-five adult patients fulfilling DSM-IV criteria for schizophrenia and presenting a depressive episode were randomised to amisulpride (200–600 mg/day) or olanzapine (5–15 mg/day) for 8 weeks. Primary efficacy variables were change in Calgary Depression Scale (CDS) score and Clinical Global Impression (CGI) of Change. Safety was monitored by adverse event reporting and determination of extrapyramidal function and metabolic variables.ResultsThe mean change from baseline of CDS score was –6.84 in the amisulpride group and –7.36 in the olanzapine group. 65.9% and 61.5% of subjects, respectively, were considered “much” or “very much” improved. No significant inter-group difference in effect size was observed. The frequency of adverse events was low and emergence of extrapyramidal symptoms was not seen. Four patients in the olanzapine group developed abnormal triglyceride levels. Mean weight gain was 1.45 and 0.5 kg, respectively, in the olanzapine and amisulpride groups.ConclusionAmisulpride and olanzapine are effective in patients with schizophrenia and comorbid depression. Tolerance of both drugs was acceptable, although use of olanzapine was associated with a trend toward greater metabolic side-effects [19].
Collapse
Affiliation(s)
- J-M Vanelle
- Service de Psychiatrie, Hôpital Saint-Jacques, 85, rue Saint-Jacques, 44200 Nantes, France.
| | | |
Collapse
|
3
|
Carta MG, Paribello P, Nardi AE, Preti A. Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder. Expert Opin Pharmacother 2019; 20:1743-1754. [DOI: 10.1080/14656566.2019.1637419] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- Mauro Giovanni Carta
- Department of Health Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - Pasquale Paribello
- Department of Health Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - Antonio Egidio Nardi
- Medical School - Institute of Psychiatry, Federal University of Rio de Janeiro National Academy of Medicine, Rio de Janeiro, Brazil
| | - Antonio Preti
- Department of Health Sciences and Public Health, University of Cagliari, Cagliari, Italy
| |
Collapse
|
4
|
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J 2016; 52:159-72. [PMID: 27689026 PMCID: PMC5040765 DOI: 10.4068/cmj.2016.52.3.159] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 06/15/2016] [Accepted: 06/16/2016] [Indexed: 12/23/2022] Open
Abstract
Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.
Collapse
Affiliation(s)
- Sheng-Min Wang
- Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.; International Health Care Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
| | - Changsu Han
- Department of Psychiatry, College of Medicine, Korea University, Korea
| | - Soo-Jung Lee
- Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea
| | - Tae-Youn Jun
- Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea
| | - Ashwin A Patkar
- Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA
| | | | - Chi-Un Pae
- Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.; Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA
| |
Collapse
|
5
|
Odds ratios of treatment response were well approximated from continuous rating scale scores for meta-analysis. J Clin Epidemiol 2015; 68:740-51. [PMID: 25801601 DOI: 10.1016/j.jclinepi.2015.02.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Revised: 02/05/2015] [Accepted: 02/09/2015] [Indexed: 11/21/2022]
Abstract
OBJECTIVES To empirically evaluate the performance of methods for estimating odds ratios and their corresponding standard errors from continuous end point data for meta-analysis. STUDY DESIGN AND SETTING A database of randomized controlled trials of chronic depression treatments was used. Trials that reported both continuous and dichotomous end points for symptom improvement were considered. Odds ratios and standard errors were calculated from the dichotomous data and estimated from the continuous data using currently available methods: Hasselblad and Hedges (HH), Cox and Snell (CS), Furukawa (F), Suissa (S), and Kraemer and Kupfer (KK). Single and meta-analytically pooled observed and estimated values were compared. RESULTS A total of 26 trials were included. At the trial level, four of five (HH, CS, F, and S) and three of four (HH, F, and S) methods for estimating odds ratios and standard errors performed well, respectively. We found considerable differences in the performance of all methods across trials with more accurate estimates for smaller treatment effects. At the level of meta-analysis, three of four methods (CS, F, and S) performed acceptably. CONCLUSION Odds ratios and standard errors can be approximated from continuous end points, but we recommend sensitivity and subgroup analyses to test robustness of the findings.
Collapse
|
6
|
Lin ST, Chen CC, Tsang HY, Lee CS, Yang P, Cheng KD, Li DJ, Wang CJ, Hsieh YC, Yang WC. Association Between Antipsychotic Use and Risk of Acute Myocardial Infarction. Circulation 2014; 130:235-43. [DOI: 10.1161/circulationaha.114.008779] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Background—
Antipsychotic medications have been increasingly and more widely prescribed despite continued uncertainty about their association with the incidence of acute myocardial infarction (AMI).
Methods and Results—
We investigated the risk of AMI associated with antipsychotic treatment in 56 910 patients with schizophrenia, mood disorders, or dementia first hospitalized or visiting an emergency room for AMI in 1999 to 2009. A case-crossover design was used to compare the distributions of antipsychotic exposure for the same patient across 1 to 30 and 91 to 120 days just before the AMI event. Adjustments were made for comedications and outpatient visits. The adjusted odds ratio of AMI risk was 2.52 (95% confidence interval, 2.37–2.68) for any antipsychotics, 2.32 (95% confidence interval, 2.17–2.47) for first-generation antipsychotics, and 2.74 (95% confidence interval, 2.49–3.02) for second-generation antipsychotics. The risk significantly increased (
P
<0.001) with elevations in dosage and in short-term use (≤30 days). Male patients, elderly patients, and patients with dementia were at significantly increased risk (all
P
<0.001). Physically healthier patients with no preexisting diabetes mellitus, hypertension, or dyslipidemia were at significantly greater risk (
P
<0.001), largely because they had been exposed to higher doses of antipsychotics (
P
<0.001). A study of the selected binding of antipsychotics to 14 neurotransmitter receptors revealed only dopamine type 3 receptor antagonism to be significantly associated with AMI risk (adjusted odds ratio, 2.59; 95% confidence interval, 2.43–2.75;
P
<0.0001).
Conclusions—
Antipsychotic use may be associated with a transient increase in risk for AMI, possibly mediated by dopamine type 3 receptor blockades. Further education on drug safety and research into the underlying biological mechanisms are needed.
Collapse
Affiliation(s)
- Shuai-Ting Lin
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Cheng-Chung Chen
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Hin-Yeung Tsang
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Chee-Siong Lee
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Pinchen Yang
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Kai-Da Cheng
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Dian-Jeng Li
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Chin-Jen Wang
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Yung-Chi Hsieh
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| | - Wei-Cheng Yang
- From the Department of Psychiatry, Kaohsiung Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan (S.-T.L., C.-C.C., H.-Y.T., K.-D.C., D.-J.L., C.-J.W., Y.-C.H., W.-C.Y.); Graduate Institute of Medicine, College of Medicine (S.-T.L., P.Y.) and Department of Psychiatry, Faculty of Medicine (P.Y.), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; and Division of Cardiology, Department of Internal Medicine (C.-S.L.) and Department of Psychiatry (P.Y.), Kaohsiung Medical University and
| |
Collapse
|
7
|
Intoxications létales à l’amisulpride en Suisse romande depuis 2005 : concentrations sanguines thérapeutiques, toxiques et létales. TOXICOLOGIE ANALYTIQUE ET CLINIQUE 2014. [DOI: 10.1016/j.toxac.2014.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
8
|
Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 2014; 13:851-70. [DOI: 10.1586/14737175.2013.811901] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
9
|
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010:CD008121. [PMID: 21154393 DOI: 10.1002/14651858.cd008121.pub2] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Major depressive disorder (MDD) is a common condition with a lifetime prevalence of 15% to 18%, which leads to considerable suffering and disability. Some antipsychotics have been reported to induce remission in major depression, when added to an antidepressant. OBJECTIVES To evaluate the effects of second-generation antipsychotic (SGA) drugs (alone or augmentation) compared with placebo or antidepressants for people with MDD or dysthymia. SEARCH STRATEGY The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on clinicaltrials.gov and contacted key authors and drug companies. SELECTION CRITERIA We included all randomised, double-blind trials comparing oral SGA treatment (alone or augmentation) with other forms of pharmaceutical treatment or placebo in people with MDD or dysthymia. DATA COLLECTION AND ANALYSIS We extracted data independently. For dichotomous data we calculated the odds ratio (OR) and 95% confidence interval (CI) on an intention-to-treat basis, and for continuous data the mean difference (MD), based on a random-effects model. We presented each comparison separately; we did not perform a pooled data analysis. MAIN RESULTS We included 28 trials with 8487 participants on five SGAs: amisulpride, aripiprazole, olanzapine, quetiapine and risperidone.Three studies (1092 participants) provided data on aripiprazole augmentation in MDD. All efficacy data (response n = 1092, three RCTs, OR 0.48; 95% CI 0.37 to 0.63), (MADRS n = 1077, three RCTs, MD -3.04; 95% CI -4.09 to -2) indicated a benefit for aripiprazole but more side effects (weight gain, EPS) .Seven trials (1754 participants) reported data on olanzapine. Compared to placebo fewer people discontinued treatment due to inefficacy; compared to antidepressants there were no efficacy differences, olanzapine augmentation showed symptom reduction (MADRS n = 808, five RCTs, MD -2.84; 95% CI -5.48 to -0.20), but also more weight or prolactin increase.Quetiapine data are based on seven trials (3414 participants). Compared to placebo, quetiapine monotherapy (response n = 1342, three RCTs, OR 0.52; 95% CI 0.41 to 0.66) and quetiapine augmentation (response n = 937, two RCTs, OR 0.68; 95% CI 0.52 to 0.90) showed symptom reduction, but quetiapine induced more sedation.Four trials (637 participants) presented data on risperidone augmentation, response data were better for risperidone (n = 371, two RCTs, OR 0.57; 95% CI 0.36 to 0.89) but augmentation showed more prolactin increase and weight gain.Five studies (1313 participants) presented data on amisulpride treatment for dysthymia. There were some beneficial effects compared to placebo or antidepressants but tolerability was worse. AUTHORS' CONCLUSIONS Quetiapine was more effective than placebo treatment. Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo. Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people. Most SGAs showed worse tolerability.
Collapse
Affiliation(s)
- Katja Komossa
- Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Möhlstr. 26, München, Germany, 81675
| | | | | | | | | |
Collapse
|
10
|
Abstract
Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antidepressant effect may contribute. In first-episode patients amisulpride is an option, although there is little comparative work available. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is evidence that amisulpride can improve social function but again there is little comparative work to demonstrate any particular advantages. Regarding the current conventional versus atypical antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer advantages over other atypical antipsychotic drugs in the treatment of negative and depressive symptoms, and tolerability advantages such as the avoidance of weight gain. Essentially it rests with the treating clinician to employ a rational psychopharmacological approach towards the individual patient: there will be few circumstances in which amisulpride will not be a likely contender as a treatment choice.
Collapse
Affiliation(s)
- Ann M Mortimer
- Department of Psychiatry, Hertford Building, The University of Hull, Cottingham Road, Hull HU6 7RX, United Kingdom.
| |
Collapse
|
11
|
Taoka H, Hamamura T, Endo S, Miyata S, Toma K, Ishihara T, Kuroda S. Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum. Psychopharmacology (Berl) 2008; 201:229-35. [PMID: 18777019 DOI: 10.1007/s00213-008-1264-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2007] [Accepted: 07/18/2008] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Recently, second-generation antipsychotics (SGAs) have been widely used in the treatment of mood disorders. However, the mechanisms of the antidepressant effect of SGAs remain unclear. We proposed that Golf protein, a stimulant alpha-subunit of G protein coupled with the dopamine D1 receptor, might a play the key role in the antidepressive effect of antidepressants. To clarify the relationship between Golf protein and the antidepressive effects of antipsychotics, we examined the effects of chronic treatment with several antipsychotics on the level of Golf protein in the rat striatum. MATERIALS AND METHODS Male Wistar rats were treated with one of several antipsychotics for 2 weeks: olanzapine (2, 5, or 10 mg/kg), sulpiride (5, 10, or 50 mg/kg), amisulpride (3, 10, or 20 mg/kg), risperidone (0.2 or 2 mg/kg), haloperidol (0.3 or 3 mg/kg), or clozapine (2 or 10 mg/kg). RESULTS AND DISCUSSION Olanzapine (5 mg/kg), sulpiride (5, or 10 mg/kg), and amisulpride (10 mg/kg) treatments significantly increased the level of Golf protein, but there was no increase with administration of higher doses of these three antipsychotics. Risperidone, haloperidol, and clozapine treatment did not change the level of Golf protein at any dose. In this study, all antipsychotics that have antidepressive effects increased Golf protein. This suggests that an increase in Golf may play an important role in the antidepressive effect of antipsychotics. CONCLUSION We postulate that the increase in Golf protein levels result in an increase the proportion of D1 receptors in the high-affinity state and that augmentation of the dopaminergic system exerts the antidepressant effect.
Collapse
Affiliation(s)
- Hideki Taoka
- Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, and Okayama Red Cross General Hospital, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan
| | | | | | | | | | | | | |
Collapse
|
12
|
Carvalho AF, Nunes-Neto PR, Cavalcante JL, Oliveira Lima MC. Amisulpride augmentation after the failure of citalopram for depression: a case report. J Clin Pharm Ther 2007; 32:97-9. [PMID: 17286793 DOI: 10.1111/j.1365-2710.2007.00787.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This case report describes a 35-year-old woman with a first depressive episode. She was treated with the serotonergic antidepressant citalopram for 12 weeks without therapeutic response. Low-dose amisulpride augmentation resulted in a significant clinical improvement. We hypothesize that the dopaminergic properties of amisulpride might augment the effects of serotonergic antidepressants in refractory patients.
Collapse
Affiliation(s)
- A F Carvalho
- Department of Clinical Medicine, Psychiatry Outpatient Clinics, Federal University of Ceará, Fortaleza, CE, Brazil.
| | | | | | | |
Collapse
|
13
|
Abstract
Efficacy studies suggest that all kinds of treatment have similar efficacy. For instance, according to a meta-analysis from 102 randomised controlled trials in major depression, there is no overall difference in efficacy between SSRIs and TCAs. Taking into consideration the pathophysiological heterogeneity of affective disorders involving a number of neurotransmitters, the different pharmacodynamic profiles of the antidepressant compounds, and the large variety of presentations of depressive illness, it is very simplistic to suppose that all classes of antidepressants are equally effective. Meanwhile, the development of antidepressants with different mechanisms of action provides the opportunity to evaluate whether certain relevant subtypes of depressed patients, based on specific patterns of symptoms, respond preferentially to one class of antidepressants compared with another. The aim of this paper is to review the relationship between the depressive subtypes included in the DSM-IV (melancholic depression, atypical depression, bipolar depression, psychotic bipolar and dysthymia) and the efficacy of antidepressant treatment.
Collapse
|
14
|
Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Amisulpride may help alcoholics in the early postdetoxification phase. J Clin Psychopharmacol 2005; 25:396-8. [PMID: 16012291 DOI: 10.1097/01.jcp.0000170031.70437.e7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Abstract
Depression is a frequent symptom in psychiatry, either isolated (major depression) or entangled with other psychiatric symptoms (psychotic depression, depression of bipolar disorders). Many antidepressant drugs are available with different pharmacological profiles from different classes: tricyclic antidepressants, monoamine oxydase inhibitors, selective serotonin reuptake inhibitors (SSRI). However, there are some limitations with these drugs because there is a long delay before relief for symptoms, some patients with major depression are resistant to treatment, there is a risk to induce manic symptoms in patients with bipolar disorders and these drugs have no effect on the psychotic symptoms frequently associated to major depression. The leading hypothesis for the search of more efficient new antidepressants has been the amine deficit hypothesis: noradrenaline and/or serotonin deficit and more recently dopamine deficit. Moreover, a dopamine deficit has been also hypothesized as the central mechanism explaining the negative symptoms of schizophrenia. These symptoms are the consequence of a deficit of normal behaviours and include affective flattening, alogia, apathy, avolition and social withdrawal. There is thus a great overlap between symptoms of depression and negative symptoms of schizophrenia. Atypical antipsychotics, in contrast with conventional neuroleptics, have been shown to decrease negative symptoms, most probably through the release of dopamine in prefrontal cortex, thus improving psychomotor activity, motivation, pleasure, appetite, etc. The dopamine deficit in cortical prefrontal areas was thus an unifying hypothesis to explain both some symptoms of depression and negative symptoms of schizophrenia. Studies in animal confirm this view and show that the association of an atypical antipsychotic drug and an SSRI (olanzapine plus fluoxetine) increases synergistically the release of dopamine in prefrontal areas. Moreover, most of the atypical antipsychotics have a large action spectrum, beyond the only dopamine receptors: their effects on the serotonin receptors--particularly the 5-HT2A and 5-HT2C receptors--suggest that their association to SSRI could be a promising treatment for depression. Indeed, SSRI act mainly by increasing the serotonin level in the synapse, thus leading to a non specific activation of all pre- and post-synaptic serotonin receptors. Among them, 5-HT2A/2C receptors have been involved in some of the unwanted effects of SSRI: agitation, anxiety, insomnia, sexual disorders, etc. The inhibition of these receptors could be thus beneficial for patients treated with SSRI. Amisulpride is an unique atypical antipsychotic that selectively blocks dopamine receptors presynaptically in the frontal cortex, possibly enhancing dopaminergic transmission. The antidepressant effect of amisulpride was shown in dysthymia in many clinical studies versus placebo, tricyclic antidepressants, SSRI or others. However, a shorter delay for symptom relief was not demonstrated for amisulpride as compared to comparative antidepressants. Other atypical antipsychotics (clozapine, olanzapine), which act on a large variety of receptors, have shown antidepressant effects--mainly in association with SSRI--in different psychiatric diseases: treatment-resistant major depression, major depression with psychotic symptoms and depression of bipolar disorders, with no increase of manic symptoms in this latter case. Moreover, the delay for symptom relief was greatly shortened. More comparative double-blind studies are required to confirm and to precise the antidepressant effects of atypical antipsychotics. Nevertheless, these studies suggest that atypical anti-psychotics could be of great value in depressive conditions reputed for their resistance to treatment with usual antidepressants. Particularly, new strategies emerge that combine atypical antipsychotics and antidepressants for greater efficacy and more rapid relief of depression symptoms.
Collapse
MESH Headings
- Affective Disorders, Psychotic/diagnosis
- Affective Disorders, Psychotic/drug therapy
- Affective Disorders, Psychotic/psychology
- Antidepressive Agents/adverse effects
- Antidepressive Agents/therapeutic use
- Antipsychotic Agents/adverse effects
- Antipsychotic Agents/therapeutic use
- Bipolar Disorder/diagnosis
- Bipolar Disorder/drug therapy
- Bipolar Disorder/psychology
- Depressive Disorder, Major/diagnosis
- Depressive Disorder, Major/drug therapy
- Depressive Disorder, Major/psychology
- Dopamine/metabolism
- Drug Synergism
- Drug Therapy, Combination
- Frontal Lobe/drug effects
- Humans
- Receptor, Serotonin, 5-HT2A/drug effects
- Receptor, Serotonin, 5-HT2C/drug effects
- Selective Serotonin Reuptake Inhibitors/adverse effects
- Selective Serotonin Reuptake Inhibitors/therapeutic use
- Syndrome
Collapse
Affiliation(s)
- Ph Quintin
- Lilly France, 13 rue Pagès, 92158 Suresnes cedex, France.
| | | |
Collapse
|
16
|
Rocca P, Marchiaro L, Rasetti R, Rivoira E, Bogetto F. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res 2002; 112:145-52. [PMID: 12429360 DOI: 10.1016/s0165-1781(02)00188-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Dysthymic disorder is a chronic depressive condition with considerable psychosocial impairment. Even if DD patients respond to various antidepressant medications, there has been little systematic study on antidepressant-refractory DD. Only a few trials have evaluated the effects of treatment on psychosocial functioning of dysthymic patients. In this 3-month, open-label study, 60 outpatients with DSM-IV criteria for dysthymic disorder who failed to respond to 3-month treatment with paroxetine 20 mg/day were randomly assigned to treatment with paroxetine 40 mg/day or paroxetine 20 mg/day plus amisulpride 50 mg/day. The effects of the two treatments were assessed for both mood symptoms (21-item Hamilton Rating Scale for Depression, Montgomery-Asberg Depression Rating Scale, Clinical Global Impression, severity and improvement) and psychosocial outcomes (DSM-IV Global Assessment of Functioning, Social Adaptation Self-evaluation Scale). Analysis of variance on all rating scales showed that both treatments were effective over this observation period. Response and remission rates did not differ in the treatment groups. A significantly greater psychosocial improvement was observed in the group receiving combined treatment compared with patients receiving paroxetine alone. Both treatments appeared to be effective in our sample of dysthymic subjects. Combined treatment with paroxetine and amisulpride resulted in a better outcome in terms of social functioning.
Collapse
Affiliation(s)
- Paola Rocca
- Department of Neuroscience, Psychiatric Section, University of Turin, Via Cherasco 11, Italy.
| | | | | | | | | |
Collapse
|
17
|
Müller MJ, Wetzel H, Benkert O. Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. Int Clin Psychopharmacol 2002; 17:249-61. [PMID: 12177587 DOI: 10.1097/00004850-200209000-00005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
While many acutely ill schizophrenic patients suffer from depressive symptoms, most studies on the efficacy of antipsychotic drugs focus on positive and negative symptoms. Dimensional models of schizophrenic symptoms, based on confirmatory factor analysis (CFA) using structural equation modelling, offer a methodological alternative to compare antipsychotics on empirically justified latent factors. The present report is a refined analysis of a published double-blind study on the D2/D3-selective antagonist amisulpride (ASP) versus the mixed D1-5/5-HT2 antagonist flupentixol (FPX). CFA was applied to Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Bech-Rafaelsen Melancholia Scale and Simpson-Angus Scale subscores to examine differential effects of high doses of ASP and FPX on negative and depressive symptom dimensions in 126 acutely ill schizophrenic patients. A four-factor model comprising the full spectrum of acute symptomatology and a three-factor model ('negative', 'anhedonia-apathy', 'depressive') restricted to negative and depressive symptoms were yielded with an identical 'depressive' dimension in both models. Analyses of CFA-derived factor scores showed that ASP was significantly superior to FPX regarding the latent 'depressive' dimension, independent of baseline scores, dosage and changes in akinesia. Neither the negative' dimension nor 'anhedonia-apathy' showed significantly different treatment effects. CFA-based analyses appear to be suitable for psychotropic drug evaluation when more refined and data-related information on drug efficacy profiles are required.
Collapse
Affiliation(s)
- M J Müller
- Department of Psychiatry, University of Mainz, Germany.
| | | | | |
Collapse
|
18
|
Rocca P, Fonzo V, Ravizza L, Rocca G, Scotta M, Zanalda E, Bogetto F. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord 2002; 70:313-7. [PMID: 12128243 DOI: 10.1016/s0165-0327(01)00327-5] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The purpose of this study was to provide preliminary data on the effects of paroxetine and amisulpride on depressive dimensions, analyzed by factor analysis, in dysthymic patients. METHODS One hundred and eighteen patients with DSM IV criteria for DD without concurrent major depression were enrolled in this 8-week, open study, and 100 completed it. Symptom dimensions were identified by principal components analysis with the SAS Factor procedure. RESULTS Results of the symptom rating scales indicated that both drugs were equally effective. Response rate was 65% both in the paroxetine and the amisulpride group and the proportions of patients achieving a final HRSD score < or =7 were 46.7 and 55%, respectively. MADRS factor analysis identified two factors at baseline: the first corresponding to the global severity of depression and the second to somatic symptoms. After 8 weeks of treatment only one factor could be substantiated. At week 4 both paroxetine and amisulpride produced significant improvements on factor 1 while at week 8 mean changes of factor 1 were greater in the amisulpride-treated patients. LIMITATIONS The main limitation was the open-label design. CONCLUSIONS Both paroxetine and amisulpride appear to be effective in the short-term management of DD, improving its most characteristic symptoms.
Collapse
Affiliation(s)
- Paola Rocca
- Department of Neuroscience, Psychiatric Section, University of Turin, via Cherasco 11, 10126 Torino, Italy.
| | | | | | | | | | | | | |
Collapse
|
19
|
Marchese G, Ruiu S, Casti P, Saba P, Gessa GL, Pani L. Effect of the amisulpride isomers on rat prolactinemia. Eur J Pharmacol 2002; 448:263-6. [PMID: 12144950 DOI: 10.1016/s0014-2999(02)01990-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The effects on rat serum prolactin level of the two isomers constituting the racemic form of amisulpride were compared. (S-)-amisulpride induced hyperprolactinemia at lower doses (ED(50) = 0.09 +/- 0.01 mg/kg) than racemic- (ED(50) = 0.24 +/- 0.03 mg/kg) and (R+)-amisulpride (ED(50) = 4.13 +/- 0.05 mg/kg), in accord with their affinities for pituitary dopamine D(2) receptor (K(i) = 3.8 +/- 0.2, 6.4 +/- 0.2 and 143.3 +/- 2.3 nM, respectively). At doses twice the ED(50), (S-)-amisulpride produced a maximal increase in prolactin level similar to that of the racemic form (403 +/- 21% and 425 +/- 15%, respectively), but higher than that of (R+)-amisulpride (198 +/- 8%). These results suggest that the hyperprolactinemia induced by the racemic-amisulpride is mostly due to its (S-)-isomer.
Collapse
|
20
|
Marchese G, Ruiu S, Casti P, Bartholini F, Saba P, Gessa GL, Pani L. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. Eur J Pharmacol 2002; 447:109-14. [PMID: 12106810 DOI: 10.1016/s0014-2999(02)01896-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Prolactin blood level and apomorphine-induced yawning were studied in rats treated with the substituted benzamide amisulpride in association with bromocriptine or carmoxirole; two dopamine D(2) receptor agonists with high or low propensity to cross the brain-blood barrier, respectively. Administration of amisulpride produced a maximum increase in rat serum prolactin level (315+/-18%) vs. vehicle-treated animals (ED(50)=0.25+/-0.017 mg/kg, s.c.). The concurrent administration of carmoxirole or bromocriptine completely reversed the hyperprolactinemia induced by amisulpride (0.5 mg/kg, s.c.) (ID(50)=14.9+/-0.8 mg/kg and 0.81+/-0.03 mg/kg, respectively). Carmoxirole (15 mg/kg, i.p.) did not affect yawning induced by apomorphine (0.08 mg/kg, s.c.) nor amisulpride (0.5 mg/kg, s.c.) blockade of apomorphine-induced yawning. Conversely, a significant increase in the number of yawns was observed when bromocriptine (0.8 mg/kg, i.p.) was associated with apomorphine in the absence or presence of amisulpride. These results suggested that a peripheral dopamine D(2) receptor agonists could be a useful tool in alleviating amisulpride-induced hyperprolactinemia without possibly affecting its central effect.
Collapse
|
21
|
Göpel C, Marcus A. Erste Erfahrungen mit Amisulprid, einem in Deutschland neuen, atypischen Neuroleptikum in der Behandlung von Jugendlichen mit psychischen Erkrankungen. ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE 2001. [DOI: 10.1024//1422-4917.29.3.230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Zusammenfassung: Fragestellung: Neben den klassischen Neuroleptika finden bei Jugendlichen zunehmend atypische Neuroleptika zur Behandlung schizophrener und schizoaffektiver Psychosen Verwendung. Seit Beginn des Jahres 1999 ist in Deutschland in der Behandlung akuter schizophrener Psychosen ein neues, offensichtlich wirkungsvolles Neuroleptikum aus der Gruppe der Benzamide verfügbar: Amisulprid. Erste Erfahrungen mit der Anwendung von Amisulprid werden berichtet. Methode: Zehn gut dokumentierte Behandlungsverläufe bei Jugendlichen unter Behandlung mit Amisulprid werden hinsichtlich Effektivität, unerwünschter Wirkungen und Dosierung berichtet. Ergebnisse: Erste Erfahrungen im Einsatz von Amisulprid sind insbesondere wegen der erheblich günstigeren Nebenwirkungsprofile bei überzeugender antipsychotischer Wirksamkeit vielversprechend. Schlussfolgerungen: Amisulprid scheint bei solchen Jugendlichen eine geeignete pharmakotherapeutische Alternative zu sein, die ein erhöhtes Auftreten von Nebenwirkungen unter atypischer neuroleptischer Medikation zeigen. Kontrollierte Studien sind nötig, um die Effektivität und Sicherheit dieser Substanz auch im Jugendalter sicher einschätzen zu können.
Collapse
Affiliation(s)
- Ch. Göpel
- Abteilung für Kinder- und Jugendpsychiatrie, Krankenanstalt Mutterhaus der Borromäerinnen, Trier, Germany
| | - A. Marcus
- Akademisches Lehrkrankenhaus (Leiter: PD Dr. A. Marcus), Johannes-Gutenberg-Universität Mainz, Germany
| |
Collapse
|